Wells Fargo
FENC icon

Wells Fargo’s Fennec Pharmaceuticals FENC Stock Holding History

Wells Fargo’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
26,564
+15,667
+144% +$128K ﹤0.01% 4971
2026
Q1 		$67K Sell
10,897
-15,262
-58% -$118K ﹤0.01% 5319
2025
Q4 		$201K Buy
26,159
+9,144
+54% +$75.1K ﹤0.01% 5067
2025
Q3 		$159K Buy
17,015
+2,756
+19% +$23.9K ﹤0.01% 5061
2025
Q2 		$118K Buy
14,259
+598
+4% +$4.09K ﹤0.01% 5099
2025
Q1 		$83.2K Buy
13,661
+509
+4% +$3.27K ﹤0.01% 5195
2024
Q4 		$83.1K Buy
13,152
+3,155
+32% +$16.2K ﹤0.01% 5297
2024
Q3 		$50K Buy
9,997
+302
+3% +$1.75K ﹤0.01% 5343
2024
Q2 		$59.2K Buy
9,695
+3,676
+61% +$30.5K ﹤0.01% 5232
2024
Q1 		$66.9K Buy
6,019
+795
+15% +$7.98K ﹤0.01% 5134
2023
Q4 		$58.6K Buy
5,224
+1,088
+26% +$9.01K ﹤0.01% 5208
2023
Q3 		$31.1K Sell
4,136
-2,814
-40% -$22.9K ﹤0.01% 5418
2023
Q2 		$61.4K Buy
6,950
+6,644
+2,171% +$55.2K ﹤0.01% 5327
2023
Q1 		$2.55K Buy
+306
New +$2.84K ﹤0.01% 6188
2021
Q4 		– Sell
-1,400
Closed -$13K – 7383
2021
Q3 		$13K Hold
1,400
– – ﹤0.01% 6111
2021
Q2 		$10K Sell
1,400
-184,509
-99% -$1.23M ﹤0.01% 6137
2021
Q1 		$1.16M Buy
185,909
+130,941
+238% +$986K ﹤0.01% 4148
2020
Q4 		$409K Buy
54,968
+4,122
+8% +$31.4K ﹤0.01% 4661
2020
Q3 		$308K Buy
50,846
+38,097
+299% +$269K ﹤0.01% 4693
2020
Q2 		$106K Buy
12,749
+10,949
+608% +$81.4K ﹤0.01% 5199
2020
Q1 		$11K Buy
+1,800
New +$11.7K ﹤0.01% 5730
2019
Q3 		– Sell
-1,074
Closed -$4K – 6475
2019
Q2 		$4K Sell
1,074
-14,334
-93% -$60.7K ﹤0.01% 6066
2019
Q1 		$75K Sell
15,408
-17
-0.1% -$112 ﹤0.01% 5216
2018
Q4 		$98K Buy
15,425
+13,641
+765% +$95.3K ﹤0.01% 5290
2018
Q3 		$14K Buy
1,784
+396
+29% +$3.67K ﹤0.01% 5912
2018
Q2 		$14K Buy
+1,388
New +$16.5K ﹤0.01% 5890

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wells Fargo's FENC Position: Q2 2026 in Review

Wells Fargo increased its Fennec Pharmaceuticals (FENC) stake by 144% in Q2 2026, buying an estimated $128K and bringing the position to 26,564 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #4971.

Wells Fargo first reported a position in FENC in Q2 2018 and has held it in 26 quarters since. The position peaked at $1.16M in Q1 2021. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Wells Fargo held 26,564 shares of Fennec Pharmaceuticals worth $286K as of Q2 2026.
  • Wells Fargo bought 15,667 Fennec Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4971 holding.
  • Wells Fargo first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 26 quarters since.
  • Wells Fargo's Fennec Pharmaceuticals position peaked at $1.16M in Q1 2021.
  • 104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.